241 related articles for article (PubMed ID: 37038127)
21. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
[TBL] [Abstract][Full Text] [Related]
23. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
Atwell JE; Lutz CS; Sparrow EG; Feikin DR
Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
[TBL] [Abstract][Full Text] [Related]
24. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
Ektare V; Lang J; Choi Y; Finelli L
Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
[TBL] [Abstract][Full Text] [Related]
25. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
[TBL] [Abstract][Full Text] [Related]
26. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
Lee Mortensen G; Harrod-Lui K
Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
[TBL] [Abstract][Full Text] [Related]
27. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
[TBL] [Abstract][Full Text] [Related]
28. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
30. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries.
Carbonell-Estrany X; Rodgers-Gray BS; Paes B
Expert Rev Anti Infect Ther; 2021 Apr; 19(4):419-441. PubMed ID: 32972198
[TBL] [Abstract][Full Text] [Related]
31. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
[TBL] [Abstract][Full Text] [Related]
32. Adjustable Algorithmic Tool for Assessing the Effectiveness of Maternal Respiratory Syncytial Virus (RSV) Vaccination on Infant Mortality in Developing Countries.
Cevigney R; Leary C; Gonik B
Infect Dis Obstet Gynecol; 2021; 2021():5536633. PubMed ID: 34121834
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis.
Hodgson D; Pebody R; Panovska-Griffiths J; Baguelin M; Atkins KE
BMC Med; 2020 Nov; 18(1):348. PubMed ID: 33203423
[TBL] [Abstract][Full Text] [Related]
34. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales.
Lang JC; Kura K; Garba SM; Elbasha EH; Chen YH
Vaccine; 2024 Mar; 42(8):1918-1927. PubMed ID: 38368224
[TBL] [Abstract][Full Text] [Related]
36. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
38. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.
Poletti P; Merler S; Ajelli M; Manfredi P; Munywoki PK; Nokes D; Melegaro A
BMC Med; 2015 Mar; 13():49. PubMed ID: 25857701
[TBL] [Abstract][Full Text] [Related]
39. A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.
Maculaitis MC; Hauber B; Beusterien KM; Will O; Kopenhafer L; Law AW; Vietri JT; Cappelleri JC; Coulter JR; Pugh S; Shea KM
Hum Vaccin Immunother; 2024 Dec; 20(1):2358566. PubMed ID: 38847198
[TBL] [Abstract][Full Text] [Related]
40. RSV disease in infants and young children: Can we see a brighter future?
Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
